Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$4.7 million.

  • Tarsus Pharmaceuticals' Cash from Investing Activities fell 25163.04% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.0 million, marking a year-over-year decrease of 2397.29%. This contributed to the annual value of -$199.2 million for FY2024, which is 24167.09% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Cash from Investing Activities of -$4.7 million as of Q3 2025, which was down 25163.04% from -$51.7 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $64.1 million during Q2 2023, with a 5-year trough of -$102.2 million in Q1 2024.
  • For the 5-year period, Tarsus Pharmaceuticals' Cash from Investing Activities averaged around -$15.5 million, with its median value being -$175000.0 (2021).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 4711239.67% in 2022, then surged by 5263442.62% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Cash from Investing Activities stood at -$274000.0 in 2021, then tumbled by 31731.75% to -$87.2 million in 2022, then skyrocketed by 120.47% to $17.8 million in 2023, then tumbled by 433.75% to -$59.6 million in 2024, then skyrocketed by 92.04% to -$4.7 million in 2025.
  • Its Cash from Investing Activities was -$4.7 million in Q3 2025, compared to -$51.7 million in Q2 2025 and -$34.9 million in Q1 2025.